2022
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
Li B, Falchook G, Durm G, Burns T, Skoulidis F, Ramalingam S, Spira A, Bestvina C, Goldberg S, Veluswamy R, Iams W, Chiappori A, Lemech C, Meloni A, Ebiana V, Dai T, Gauto D, Varrieur T, Snyder W, Govindan R. OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC. Journal Of Thoracic Oncology 2022, 17: s10-s11. DOI: 10.1016/j.jtho.2022.07.025.Peer-Reviewed Original Research
2020
Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Felip E, Lim F, Johnson M, O'Brien M, Barlesi F, Mazieres J, Solomon B, Moreno V, Boni V, Swalduz A, Goldberg S, Keam B, Allen S, Helms H, Shemesh C, Pintoffl J, Al-Sakaff N, Bailey L, Sayyed P, Cho B. Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer). Annals Of Oncology 2020, 31: s850. DOI: 10.1016/j.annonc.2020.08.1629.Peer-Reviewed Original Research